Global Prostate Specific Antigen (PSA) Biomarker Market Growth (Status and Outlook) 2025-2031

According to this study, the global Prostate Specific Antigen (PSA) Biomarker market size will reach US$ million by 2031.

Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the level of PSA in a man"s blood. For this test, a blood sample is sent to a laboratory for analysis.

United States market for Prostate Specific Antigen (PSA) Biomarker is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Prostate Specific Antigen (PSA) Biomarker is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Prostate Specific Antigen (PSA) Biomarker is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Prostate Specific Antigen (PSA) Biomarker players cover Abbott, Siemens Healthcare, DiaSorin, Roche, Tosoh Bioscience, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Prostate Specific Antigen (PSA) Biomarker Industry Forecast” looks at past sales and reviews total world Prostate Specific Antigen (PSA) Biomarker sales in 2024, providing a comprehensive analysis by region and market sector of projected Prostate Specific Antigen (PSA) Biomarker sales for 2025 through 2031. With Prostate Specific Antigen (PSA) Biomarker sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Prostate Specific Antigen (PSA) Biomarker industry.

This Insight Report provides a comprehensive analysis of the global Prostate Specific Antigen (PSA) Biomarker landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Prostate Specific Antigen (PSA) Biomarker portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Prostate Specific Antigen (PSA) Biomarker market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Prostate Specific Antigen (PSA) Biomarker and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Prostate Specific Antigen (PSA) Biomarker.

This report presents a comprehensive overview, market shares, and growth opportunities of Prostate Specific Antigen (PSA) Biomarker market by product type, application, key players and key regions and countries.

Segmentation by Type:
Blood
Semen
Urine

Segmentation by Application:
Diagnostics
Drug Discovery
Personalized Medicine
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott
Siemens Healthcare
DiaSorin
Roche
Tosoh Bioscience
Fujirebio
BodiTech
GE Healthcare
Endocare
Quest Diagnostics
Bio-Rad Laboratories
QIAGEN
Myriad RBM

Please note: The report will take approximately 2 business days to prepare and deliver. Show more